-
Company Nameaiwell Inc.
-
EstablishmentJanuary 23, 2018
-
RepresentativeHIROYUKI MABUCHI
-
Location
-
Head Office
〒102-0084 -
Campus Innovation Center Tamachi
〒108-0023 -
Branch
Sapporo -
Proteomics Innovation Center(PIC)
9-3 Nibancho, Chiyoda-ku, Tokyo
Tokyo Institute of Technology Campus Innovation Center INDEST
3rd floor #302-3
〒060-0908
4-1-20 Kitahachijo Higashi, Higashi-ku, Sapporo-shi, Hokkaido
2nd Floor, Satudora Holdings
EZOHUB SAPPORO
〒650-0047
6-3-7 Minatojima Minamimachi, Chuo-ku, Kobe
PIC Shin Kawasaki
Creative Lab Kobe
〒212-0032
Room 221, KBIC Main Building, 7-7 Shin-Kawasaki, Saiwai-ku, Kawasaki City, Kanagawa -
Head Office
-
Capital450,133,500 yen (as of Dec 2023)
-
Main ShareholderRepresentative, Yokogawa Electric Corporation, Burroughs Inc, DIGIMERCE Inc, Taisho Pharmaceutical Co., Ltd., Future Food Fund Inc.,North Pacific Bank, Ltd., Contrail LLC, and individual investors
-
Business description
- Realization of mass image data intercomparison by digital imaging and analysis of proteins from human, animals and other living organisms from trace amounts of samples in collaboration with Tokyo Institute of Technology.
- Providing services to support drug discovery, diagnosis and remote medical care using AI before worsening of symptoms or onset of subjective symptoms under the mission 「Eliminating illnesses from the world and keep people healthy」
-
SuppliersTokyo Institute of Technology, Sapporo Medical University, Consadole Co., Ltd., R-body project, Kirin Holdings Co., Ltd., Yokogawa Electric Corporation. Sumitomo Dainippon Pharma Co., Ltd. Taisho Pharmaceutical Co., Ltd.